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Abstract
Atrial fibrillation is a disturbance of heart rhythm, which is characterized by frequent contractions of atrial muscle
fibers. Stable ischemic heart disease, arterial hypertension, heart failure, obesity are risk factors for progression
of atrial fibrillation. Psycho-emotional stress, anxiety and depression can be the cause of atrial fibrillation
paroxysm as well.
The objective of the research was to study the effect of mebicar in the treatment of paroxysmal atrial fibrillation
considering anxiety-depressive symptoms.
Materials and Methods. Observations were performed on patients with stable ischemic heart disease and
co-existent paroxysmal atrial fibrillation using clinico-psychopathological research method (structured interview).
The level of stress was determined on the L. Rider scale and the 10-Item perceived stress scale; the level
of anxiety and depression was determined by means of the Hospital Anxiety and Depression Scale and the
Patient Health Questionnaire-9. The evaluation of the free radical oxidation state was carried out using a
spectrophotometric method to determine the activity of catalase, glutathione peroxidase, superoxide dismutase
in the blood serum.
Results. As a result of the analysis, it was found that the higher the level of anxiety-depressive disorders, the
more frequent paroxysms of atrial fibrillation. High level of stress was found in 37.50% of men (p<0.01) and
31.25% of women (p<0.05) in Group 2b. The manifestations of the clinical level of anxiety and depression in
men of Group 2b (p<0.05) were detected.
Conclusions. The analysis of electrocardiogram indices showed the signs of atrial fibrillation (p<0.05), repo-
larization abnormalities (p<0.001), left ventricular hypertrophy (p<0.05), and the appearance of extrasystoles
(p<0.001). Echocardiographic indices showed the signs of diffuse cardiosclerosis, severe left atrial dilatation
(p<0.05) and reduced myocardial contractility, which was statistically confirmed. The use of anxiolytic medication
– mebicar – during treatment helped significantly improve the clinical and hemodynamic parameters, which
confirmed treatment effectiveness.
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Problem statement and analysis of
the latest research
Among the population of most developed European
countries, cardiovascular disease (CVD) accounts
for almost 40% of all fatal cases. According to
the World Health Organization, approximately 23.6
million people worldwide will die of CVD, namely
arrhythmias and stroke, by 2030 [1].
Atrial fibrillation (AF) is the most common
supraventricular arrhythmia with a high risk of sud-
den death and thromboembolic complications [2].
Paroxysmal form of AF is one of the most dan-
gerous cardiac rhythm disturbances and accounts
for 35% of all types of arrhythmias [3]. First off,
AF is an independent predictor of mortality due to
embolic strokes. The development of paroxysm is
preceded by a variety of factors, including stable is-
chemic heart disease (SIHD), myocardial infarction
(MI), infiltrative or inflammatory diseases of the
atria, endocrine disorders, congenital heart defects,
and surgical intervention. In apparently healthy
young people, AF paroxysms often arise as idio-
pathic AF [3].
Seventy-eighty per cent of patients with rhythm
disturbances were found to have borderline mental
disorders, namely anxiety and depression, which
impaired the clinical course of AF [3]. According
to the literature, the main pathogenetic mechanisms
of developing cardiac rhythm disturbances under
the influence of psycho-emotional stress are the
activation of the sympathetic nervous system, the
decrease in the variability of the heart rate, changes
in the platelet reactivity and platelet serotonin sys-
tem, instability of the myocardium due to ischemia
and vasoconstriction, excessive free radical produc-
tion and the development of oxidative stress [4]. To
date, there are several theories of arrhythmias in car-
diology: the theory of re-entry, the type of micro or
macro re-entry with the development of functional
blockade in different sections of the conducting
system, the theory of automatic ectopic excitation,
the theory of trace potential, the theory of hetero-
geneous repolarization of individual structures of
the myocardium, the theory of increasing the au-
tomatism of the conducting system cells located
below the sinus node. Among the main mecha-
nisms, which are mediated by the manifestation of
rhythm disturbances under the influence of stress,
there is the activity of the sympathetic and parasym-
pathetic divisions of the autonomic nervous system
(ANS) [1].
According to Engel C.L., the cause of sudden
cardiac death from psycho-emotional stress can be
increased activity of the sympathetic and parasym-
pathetic nervous systems [3, 5]. The increase in the
sympathetic tone, the decrease in the vagal tone and
cardiac anxiety symptoms can be the main provoca-
tive factors of AF acting as triggers and modulating
ANS [6].
The role of the sympathetic and parasympa-
thetic nervous systems in the development of heart
arte variability (HRV) was found to be as follows:
during an emotional reaction, anger occurs, sym-
pathetic activity and heart rate (HR) increase; how-
ever, HRV, that is an indicator of parasympathetic
activity, does not change. Due to this, we can con-
clude, that this is the mechanism of arrhythmogene-
sis [5]. There are many research works, that proved
the excessive production of free radicals and the
development of oxidative stress to be the leading
mechanisms of initiation and progression of AF [4].
Oxidative stress is a disturbance in the prooxidant
to antioxidant balance towards prooxidants [7, 8].
Prooxidants cause an increase in the formation
of free radicals, including smoking, pollutants, ac-
tivation of oxygen metabolites [7]. The increased
level of reactive oxygen intermediates (ROI) in the
cell promotes the initiation of negative reactions
that initiate lipid peroxidation (LPO) of cell mem-
branes resulting in damage to their structure and
increased permeability [9].
The antioxidant system of the body is known to
be able to inhibit free radical oxidation of organic
substances and products of LPO reactions [7, 9].
Enzyme antioxidants include superoxide dismutase
(SOD), which binds to ROI to form hydrogen per-
oxide; glutathione peroxidase (GP), which reduces
lipid hydroperoxides due to the oxidation of glu-
tathione; catalase, which disrupts peroxides in lipid
hydroperoxides [7]. As a result of the studies con-
ducted, the intensification of stress oxidation pro-
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cesses was proven to have a direct effect on car-
diomyocytes, contributing to the arrhythmogenic
activity of the myocardium. In modern literature,
there are only few research works devoted to the
study of oxidative stress in patients with AF [8].
The objectiv of the research was to study and
analyze the dynamics of the effect of mebicar in the
patients with SIHD and co-existent paroxysmal AF
considering anxiety-depressive symptoms.
1. Materials and Methods
Thirty-one patients with paroxysmal AF were ex-
amined in the cardiology departments of Ivano-
Frankivsk Regional Clinical Cardiology Center and
Central City Clinical Hospital. Two groups were
formed. Group 2a included 15 patients with SIHD
and co-existent paroxysmal AF who received stan-
dard therapy. Group 2b consisted of 16 patients
with SIHD and co-existent paroxysmal AF who
received standard therapy with the addition of anxi-
olytic drug mebicar. All the patients gave voluntary
informed consent to participate in the study.
Inclusion criteria included the presence of parox-
ysmal AF. Exclusion criteria included the presence
of acute, subacute, inflammatory stage of MI, con-
genital and acquired heart defects, cardiomyopathies
of various genesis, intoxication with cardiac glyco-
sides, antidepressants, diuretics, sympathomimetics
or toxic substances, thyrotoxicosis, psychiatric dis-
orders (schizophrenia, affective disorders), alcohol
addiction and psychoactive substance abuse.
The study was approved by the Hospital Re-
search Ethics Committees and conducted in accor-
dance with the World Medical Association Declara-
tion of Helsinki (1989).
In the course of the study, there was made a com-
parison between the dynamics of the course of the
main cardiological disease against the background
of standard and anxiolytic therapy.
In addition to the clinical examination, the fol-
lowing psychometric methods of research were used:
L. Rider’s Psychosocial Stress Scale, the 10-Item
perceived stress scale (PSS-10), the Hospital Anx-
iety and Depression Scale (HADS), the Patient
Health Questionnaire-9 (PHQ-9) for identifying so-
cial factors that may have an impact on health.
L. Rider’s Psychosocial Stress Scale is intended
to assess susceptibility to stress. In men, stress level
was assessed as low (0.00-0.99 points), average
(1.00-1.99 points) and high (2.00-3.00 points); in
women, it was (0.00-1.17 points), (1.18-2.17 points)
and (2.18-3.00 points) respectively.
The PSS-10 included 10 items divided by the
level of stress, where PSS-10 scores ranging 0-
13 were considered low perceived stress, PSS-10
scores ranging 14-16 were considered average per-
ceived stress, PSS-10 scores ranging 27-40 were
considered high perceived stress.
The HADS consists of 14 questions that assess
the well-being of patients during the previous week.
Patients respond to each question on a 3-point Lik-
ert’s scale. Seven of the 14 questions assess the
level of depression, and the other seven evaluate the
level of anxiety. Evaluations are summed up sepa-
rately for depression and anxiety, with a range of
0-21 points. Interpretation of results allows to differ-
entiate 3 categories of the state: normal, subclinical
and clinical anxiety/depression: 0-7 scores indi-
cate non-cases, no disorders; 8-10 scores indicate
possible case of anxiety/depression, 11 scores or
more indicate probable case of anxiety/depression.
To assess the impact of negative factors, there was
used the PHQ-9 for determining social factors that
affect health. On the first day of hospitalization
and then in the dynamics after treatment, there was
performed a standard 12-lead electrocardiogram
(ECG) while the patients rested. The MIDAS 6/12
electrocardiograph was used for ECG recording.
The evaluation of linear dimensions and vol-
ume parameters of the heart, the state of the valvu-
lar apparatus was performed by echocardiography
using the Canon Aplio 400 ultrasound machine
(USA) by means of sectoral sensor before and af-
ter treatment. The end-diastolic index (EDI) and
the end-systolic index (ESI) were calculated. In
addition, stroke volume (SV) was measured as the
difference between the volumes of the left ventricle
(LV) in diastole and systole. An important hemody-
namic parameter of the contractile function of the
LV is the ejection fraction (EF), which characterizes
the systolic function of the heart. The myocardial
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mass of the LV (MMLV) and its index, i.e., LV vol-
ume/mass ratio were determined. The relative LV
wall thickness (LVWT) was determined by the for-
mula: LVWT = 2 * LVPWd/EDD, where LVPWd
was left ventricular posterior wall thickness in dias-
tole (cm), EDD was end-diastolic dimension (cm).
The shortening of the anterior-posterior dimension
(D, %) of the LV short-axis is the distance between
the E-peak of the anterior mitral valve leaflet coap-
tation point and the interventricular septum, which
characterizes the ratio of diastolic (the apex of the
R-wave) to the systolic (the end of the T-wave) LV
dimension. The types of LV geometry in case of its
hypertrophy were calculated as follows: in the pres-
ence of LV hypertrophy (LVH) and LVWT<0.43,
eccentric LVH was diagnosed; in case of LVH and
LVWT>0.43, concentric HLV was diagnosed.
Quantitative determination of catalase accord-
ing to A. Bakh and S. Zubkova was carried out
by titration using hydrogen peroxide, sulfuric acid,
potassium permanganate, distilled water and pa-
tient’s blood. One ml of diluted solution of blood
was added to a test tube containing 2 ml of a 1%
solution of hydrogen peroxide and 7 ml of water.
After 30 minutes, 3 ml of 10% solution of sulfuric
acid were added. The resulting solution was titrated
with normal solution of potassium permanganate
until a faint pink color appeared. In healthy adults,
normal catalase value ranges within 9.52-12.92 mg
of hydrogen peroxide per ml of blood.
The SOD activity was determined on the KFK-
2MP apparatus. The following reagents were used:
0.15 M phosphate buffer (pH 7.8), incubation mix-
ture - 37 ml of EDTA-Na2 (ethylene diamine tetraac-
etate acid disodium salt), 330 ml of nitrotetrazole
blue, 55 ml of phenazine methisulphate. This mix-
ture was mixed with 300 ml of phosphate buffer
and left overnight, filtered in the morning. The cal-
culation was carried out according to the formula:
SOD (%): = Ek-Eo: Ek * 100.
The activity of GP was determined on
the SPECORD-M40 two-channel spectrophotome-
ter, using a reaction mixture comprising 1 ml of
phosphate buffer, sodium azide 12 mM-0.9 ml, 0.5
ml of 2.5 mM reconstituted glutathione, 0.2 ml of
the patient’s blood serum, 0.5 ml of H2O2. The re-
action was started by adding H2O2, stopped after 2
minutes, adding 1 ml of 10% TCO. The mixture was
centrifuged at 3, 000 rpm for 15 minutes. There was
determined the extinction of oxidized glutathione at
260 nm. The activity of the enzyme was expressed
in micromoles of oxidized glutathione per 1 Hb per
minute.
Laboratory blood tests were performed in the
morning on an empty stomach after abstaining from
food for 14 hours. Blood biochemical tests were
performed with the use of a biochemical analyzer.
The indicators of coagulation hemostasis were stud-
ied.
Statistical data processing was carried out using
Statistica-10. P-value less than 0.05 was considered
statistically significant.
2. Results and Discussion
According to the results of psychopathological ex-
amination of the patients with SIHD and co-existent
paroxysmal AF, a direct correlation between the
level of anxiety-depressive symptoms, stress sus-
ceptibility and the appearance of AF paroxysm was
revealed. The study allowed us to compare the data
before and after treatment.
During the clinical examination, the occurrence
of AF paroxysms in the studied groups was found
to be associated with acute (unexpected death of
relatives, accidents, divorce, conflicts between rela-
tives) and chronic (illnesses of relatives, financial
problems) psychosocial stress.
AF paroxysm was accompanied by the feeling
of interruptions (p>0.05), accelerated palpitation
(p>0.05), frequent changes in blood pressure (BP)
(p<0.05), cardiac rhythm disturbance (p<0.05),
signs of autonomic dysfunction, including memory
impairment (p<0.05), sleep disturbance (p<0.05),
sweating (p<0.01), general fatigue, which could
confirm the symptoms of cardiac neurorosis.
It should be noted that the patients had signs
of cardiogenic liver congestion due to heart failure
in the systemic and pulmonary circulation, which
was clinically manifested by hepatosplenomegaly
(p>0.05).
In 50.00% of men (p<0.01) and 25.00% of
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Table 1. Dynamics of the PSS-10 indices in patients with paroxysmal AF during treatment with mebicar.
Groups
Paroxysmal AF Paroxysmal AF,
(n=15) treatment with mebicar (n=16)
Group 2a Group 2b
Level of stress,
points
Men
before treatment after treatment before treatment after treatment
Low 0 (0.00%) 3 (20.00%)
0 (0.00%) 0 (0.00%)
p>0.05 p>0.05
Average 7 (46.67%) 4 (26.67%)
3 (18.75%) 8 (50.00%)
p>0,05 p>0.05
High 0 (0.00%) 0 (0.00%)
6 (37.50%) 1 (6.25%)
p<0.01 p>0.05
Level of stress,
points
Women
before treatment after treatment before treatment after treatment
Low 0 (0.00%) 0 (0.00%)
1 (6.25%) 2 (12.50%)
p>0.05 p>0.05
Average 8 (53.33%) 8 (53.33%)
1 (6.25%) 4 (25.00%)
p<0.01 p>0.05
High 0 (0.00%) 0 (0.00%)
5 (31.25%) 1 (6.25%)
p<0.05 p>0.05
Note: p - the reliability of the difference in indicators before and after treatment.
women (p>0.05) of Group 2b, a high level of stress
was found. When studying indicators of the PSS-10
among 16 surveyed patients, high levels of stress
were detected in 6 men and 5 women - 37.50%
(p<0.01) and 31.25% (p<0.05), respectively. The
average level of stress was found in 8 women -
53.33% (p<0.01). After analyzing the data, we
can conclude that the indicators of Group 2b sig-
nificantly differed from the indicators of Group 2a
(Table 1).
According to the results of the study, 25.00%
of men in Group 2b had a probable case of anxiety
and depression (p<0.05), manifested as a feeling
of emotional tension, fear, loss of vivacity, sudden
feeling of panic, depression, persistent feeling of
sadness and unwillingness to live, including suicide.
Among women, these symptoms were observed
as well; however, without a probable difference
between the scores (p>0.05). The assessment of
the dynamics of anxiety and depression according
to the HADS after treatment showed a statistically
significant (p<0.05) decrease in depressive mood
and anxiety in men of Group 2b (Table 2).
Analyzing the data of the PHQ-9, we found
that men of Group 2b complained of depressive
mood, fatigue, sleep disturbance, inability to con-
centrate, that indicated moderate depression symp-
toms (p<0.05).
On the background of taking mebicar at a dose
of 500 mg twice a day for two weeks, the manifes-
tations of emotional tension, fear, anxiety reduced,
and memory, mental capacity (p<0.05) improved.
There were no side effects when taking a tranquil-
izer.
In the patients with paroxysmal AF, statistical
accuracy of ECG indices was revealed (Table 3).
Slow depolarization of the atrium is the electro-
physiological basis of AF, which develops under
the mechanism of re-entry.
An important electrocardiographic sign of AF
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Table 2. Dynamics of the HADS indicators in patients with paroxysmal AF during treatment with
mebicar.
Groups
Paroxysmal AF Paroxysmal AF,
(n=15) treatment with mebicar (n=16)
Group 2a Group 2b
Criteria for evaluating
anxiety, scores
Men
before treatment after treatment before treatment after treatment
No disorder (norm 0-7
scores)
2 (13.33%) 7 (46.67%)
1 (6.25%) 4 (25.00%)
p>0.05 p>0.05
Subclinical level (possible
case) (8-10 scores)
5 (33.33%) 0 (0.00%)
4 (25.00%) 4 (25.00%)
p>0.05 p<0.05
Clinical level (probable
case) (11 scores or more)
0 (0.00%) 0 (0.00%)
4 (25.00%) 1 (6.25%)
p<0.05 p>0.05
Criteria for assessing de-
pression, scores
Men
before treatment after treatment before treatment after treatment
No disorder (norm 0-7
scores)
4 (26.67%) 9 (60.00%)
1 (6.25%) 3 (18.75%)
p>0.05 p<0.05
Subclinical level (possible
case) (8-10 scores)
3 (20.00%) 0 (0.00%)
4 (25.00%) 5 (31.25%0
p>0.05 p<0.05
Clinical level (probable
case) (11 scores or more)
0 (0.00%) 0 (0.00%)
4 (25.00%) 1 (6.25%)
p<0.05 p>0.05
Criteria for evaluating anx-
iety, scores
Women
before treatment after treatment before treatment after treatment
No disorder (norm 0-7
scores)
2 (13.33%) 6 (40.00%)
2 (12.50%) 3(18.75%)
p>0.05 p>0.05
Subclinical level (possible
case) (8-10 scores)
2 (13.33%) 2 (13.33%)
1 (6.25%) 4 (25.00%)
p>0.05 p>0.05
Clinical level (probable
case) (11 scores or more)
4 (26.67%) 0 (0.00%)
4 (25.00%) 0 (0.00%)
p>0.05 p>0.05
Criteria for assessing de-
pression, scores
Women
before treatment after treatment before treatment after treatment
No disorder (norm 0-7
scores)
3 (20.00%) 6 (40.00%)
2 (12.50%) 3 (18.75%)
p>0.05 p>0.05
Subclinical level (possible
case) (8-10 scores)
2 (13.33%) 2 (13.33%)
0 (0.00%) 1 (6.25%)
p>0.05 p>0.05
Clinical level (probable
case) (11 scores or more)
3 (20.00%) 0 (0.00%)
5 (31.25%) 3 (18.75%)
p>0.05 p>0.05
Note: p - the reliability of the difference in indicators before and after treatment.
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Table 3. Dynamics of ECG parameters in patients with paroxysmal AF during treatment with mebicar.
Indices
Paroxysmal AF Paroxysmal AF,
(n=15) treatment with mebicar (n=16)
Group 2a Group 2b
Indicator dynamics before treatment aftertreatment before treatment after treatment
RR 0.79±0.07 0.90±0.05 0.60±0.05 0.76±0.07
p<0.05 p>0.05
QRS – DI 0.10±0.01 0.09±0.01 0.06±0.00 0.07±0.01
p<0.01 p>0.05
T wave in V2 lead
2.27±0.56 2.43±0.71 6.00±0.00 2.69±0.82
p<0.001 p>0.05
T wave (-/+) in aVL lead 0.67±0.30 0.93±0.32 2.00±0.00 1.06±0.19
p<0,001 p>0.05
T wave (-/+) in V6 lead 2.27±0.45 1.86±0.50 4.00±0.00 1.31±0.54
p<0.001 p>0.05
ST segment 15.80±0.92 16.14±0.51 14.31±0.66 13.44±1.12
p>0.05 p<0.05
ST segment in V1 lead 13.73±0.89 14.93±0.59 14.0±0.00 11.75±0.96
p>0.05 p<0.01
RS-T segment in V6 lead 15.80±1.02 17.36±0.71 15.19±0.60 14.44±1.16
p>0.05 p<0.05
RS-T segment in I lead 15.73±1.08 17.64±0.82 13.63±1.06 13.38±1.41
p>0.05 p<0.05
CVI: R wave in aVL lead +
S wave in V3 lead >28mm
9.13±1.99 8.64±2.01 14.00±0.00 10.31±1.96
p<0.05 p>0.05
EI: R1+SIII >17 mm 12.07±0.97 13.14±1.82 17.00±0.00 12.56±1.35
p<0.05 p>0.05
PI=QR* interval /QT
interval
0.10±0.08 0.50±0.09 0.00±0.00 0.00±0.00
p>0.05 p<0.001
MI:P wave duration/PQ
segment dustion<1.1
0.18±0.07 0.50±0.09 0.14±0.07 0.21±0.07
p>0.05 p<0.05
P-Q interval 0.05±0.02 0.13±0.02 0.04±0.02 0.06±0.02
p>0.05 p<0.05
Note: p - the reliability of the difference in indicators before and after treatment.
is the irregularity of ventricular QRS complexes,
an irregular ventricular rhythm reflecting different
RR intervals (p<0.05). The T wave in the unipo-
lar leads (aVL) (p<0.001) and in thoracic leads
(V2), (V6) (p<0.001) indicates repolarization ab-
normalities. A high, symmetrical T wave explains
subendocardial ischemia of the myocardium. The
ST segment represents the ventricular excitation
process, where its duration depends on the pulse
rate (p<0.05).
An interpreting the Cornell Voltage Index (CVI)
and the Endleyden Index (EI), we noted that the
indices of both groups indicated the presence of
severe LVH, that was statistically proven (p<0.05).
The ratio of the coupling interval and the QT inter-
val is called the prematurity index (PI) and explains
the emergence of extrasystoles (p<0.001).
Having compared the data of the Macruz Index
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Table 4. Dynamics of echocardiographic indicators in patients with AF during treatment with mebicar.
Indicators, units
of measure
Paroxysmal AF Paroxysmal AF,
(n=15) treatment with mebicar (n=16)
Group 2a Group 2b
Indicator dynamics before treatment after treatment before treatment after treatment
EDD, cm 5.01±0.13 5.14±0.19 5.21±0.17
p>0.05
5.44±0.22
p>0.05
ESD, cm 3.65±0.14 3.81±0.19 3.98±0.08
p<0.05
4.01±0.20
p>0.05
EDV, ml 120.40±7.84 127.25±12.51 133.31±10.88
p>0.05
148.40±15.07
p>0.05
ESV, ml 56.47 ±6.09 63.63±8.46 68.56±8.91
p>0.05
73.00±9.06
p>0.05
TIVSd, cm 1.13±0.02 1.09±0.02 1.16±0.04
p>0.05
1.07±0.04
p>0.05
LVPWd, cm 1.10±0.03 1.08±0.04 1.16±0.02
p>0.05
1.10±0.03
p>0.05
EDI ml/m 0.37±0.03 0.38±0.05 0.35±0.02
p>0.05
0.37±0.03
p>0.05
ESI ml/m 0.18±0.02 0.19±0.03 0.23±0.05
p>0.05
0.18±0.01
p>0.05
SV, ml 62.60±2.53 63.63±4.28 64.88±3.25
p>0.05
75.40±6.26
p>0.05
EF (%) 52.07±1.26 50.25±1.39 50.19±1.30
p>0.05
51.60±1.24
p>0.05
MMLV, g 210.29±9.16 212.13±10.70 240.54±10.85
p<0.05
238.30±23.26
p>0.05
IMMLV g/m 0.66±0.05 0.64±0.06 1.02±0.38
p>0.05
0.61±0.05
p>0.05
LVWT (c.u.) 0.44±0.02 0.42±0.00 0.48±0.04
p>0.05
0.40±0.01
p<0.05
S, % 1.38±0.02 1.35±0.02 1.35±0.01
p>0.05
1.36±0.02
p>0.05
Concentric hypertrophy 10 (66.67%) 10 (66.67%) 10 (87.50%)
p>0.05
10 (87.50%)
p>0.05
Eccentric hypertrophy 5 (33.33%) 5 (33.33%) 6 (37.50%)
p>0.05
6 (37.50%)
p>0.05
LAD cm 3.84±0.15 3.89±0.14 4.29±0.14
p<0.05
4.06±0.13
p>0.05
RVD, size, cm 2.89±0.06 2.96±006 2.96±0.25
p>0.05
2.99±0.12
p>0.05
Note: p - the reliability of the difference in indicators before and after treatment.
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Table 5. Dynamics of indicators of catalase, SOD, GP activity in the blood serum of patients with
paroxysmal AF during treatment with mebicar.
Indices
Paroxysmal AF Paroxysmal AF,
(n=15) treatment with mebicar (n=16)
Group 2a Group 2b
Indicator dynamics before treatment after treatment before treatment after treatment
Catalase, mg H2O2/1ml of
blood
14.42±1.46 9.92±2.25 15.37±1.55 12.18±2.06
p>0.05 p<0.001
SOD, % 35.33±4.08 24.87±5.91 34.56±4.87 38.00±7.63
p>0.05 p<0.001
GP, mlmol, min/mg 0.14±0.03 0.10±0.03 0.16±0.02 0.11±0.02
p>0.05 p<0.01
Note: p - the reliability of the difference in indicators before and after treatment.
(MI) in Group 2a and Group 2b, where the indices
were 0.50±0.09 and 0.21±0.07, respectively, we
noted that there was a significant difference in the
indicators after treatment (p<0.05). Analyzing the
PQ interval data, we observed a shortening of its
duration depending on the HR (p<0.05).
Table 4 shows the dynamics of echocardiographic
parameters in the patients with paroxysmal AF. With
the increase in the level of anxiety-depressive symp-
toms, there was the increase in ESD, EDV, left atrial
dimension (LAD) and decrease in EF.
Having analyzed the MMLV, we found that its
mass might also depend on the level of anxiety-
depressive symptoms. Having compared the data
of Group 2a and Group 2b, where the indicators
were 210.29±9.16 and 240.54±10.85, respectively,
we noted that the indicator of Group 2b was higher,
which was statistically confirmed (p<0.05). The
value of ESD was significantly higher than that in
Group 2a (p<0.05).
Particular attention was paid to the clinical and
pathogenetic features of LA state. In hemodynamic
overload of the atria, the intra-articular pressure in-
creases, thereby leading to the atrial wall thinning
with the development of diffuse atrial sclerosis, that
results in reduced myocardial contractility due to
the overflow of its cavities with blood at the end of
the systole, which is accompanied by the dilation
of cardiac walls. As the LA has the tendency to
dilatation, it leads to AF. According to the Fram-
ingham Study, increased LA was associated with a
twofold increase in AF. The LA indicator in the pa-
tients of Group 2b was rather high - (4.29±0.14 cm),
whereas, in Group 2a, it was (3.84±0.15 cm), indi-
cating systolic dysfunction.
The study of the dynamics of free radical pro-
cesses involved the study of antioxidant enzymes.
Having analyzed the activity of catalase (Table 5),
we found that the value of this indicator depended
on the level of psycho-emotional stress. Having
compared the data between Group 2a and Group 2b,
where the values were 9.92±2.25 mg H2O2 /1 ml of
blood and 12.18±2.06 mg of H2O2 /1 ml of blood,
respectively, we noted that the indicator was higher
in Group 2b, which was statistically confirmed
(p<0.001). After interpreting SOD, we noted that
its parameters depended on the level of psycho-
emotional state as well, that was statistically proven
(p<0.001). The activity of serum GP in the pa-
tients receiving anxiolytic therapy was 0.11±0.02,
(p<0.01), which explained the positive dynamics
of treatment. Consequently, increased anxiety and
depression symptoms affected the activity of an-
tioxidant enzymes, which led to the disturbance of
free radical oxidation. Free radicals, that modify
cardiomyocyte receptors, deepened ischemia and
contributed to the arrhythmogenic effect.
There were no significant differences in the lev-
els of total bilirubin, cholesterol, total protein, crea-
tinine, alanine aminotransferase, aspartate amino-
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transferase among the examined patients (p>0.05).
The analysis of the results of urea level in Group 2a
and Group 2b was as follows: 6.67±0.49 mmol/l
and 10.09±4.97 mmol/l as compared to the nor-
mal range of 1.7-8.3 mmol/l, that might explain
the side effects of taking β -blockers or a worsened
course of cardiac disease. The indicators of the
circulatory system in the patients of Group 2b in-
dicated the signs of hypocoagulation. The relia-
bility of prothrombin time was 14.55±0.77 and
6.85±1.70 (p<0.001) and hematocrit - 0.48±0.01
and 0.43±0.01 (p<0.001) in Group 2a and Group
2b, respectively.
Thus, the results of the study suggested the oc-
currence of psychosomatic AF, in which the pa-
tients develop cardioneurosis symptoms manifest-
ing themselves as repeated episodes of AF parox-
ysms on the background of psycho-emotional stress.
Taking anxiolytic drug mebicar at a dose of 500
mg twice a day allowed reducing the manifestations
of anxiety and depression, which led to the posi-
tive dynamics in the clinical course of cardiological
disease.
3. Conclusions
1. The analysis of the clinical psychopathologi-
cal method of the study confirmed the symp-
toms of cardioneurosis, susceptibility to stress
and the clinical level of anxiety and depres-
sion.
2. Echocardiographic indices showed the signs
of diffuse cardiosclerosis, severe LA dilata-
tion and reduced myocardial contractility.
3. The functional state of the antioxidant sys-
tem showed that the higher the anxiety and
the level of depression, the higher the data
indicators.
4. Prospects of Further
Researches
Prospects for further research are the study of
the effectiveness of mebicar in the dynamics.
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